News

We are proud to announce that Nestmedic SA had been invited to take part in the HealthTech program to present its solution, the teleCTG Pregnabit system, during the “Warsaw-London Bridge” event, which was also attended by a British royal couple, Prince William and Princess Kate. Five medical start-ups had been invited to take part in the contest. All of them had an opportunity to present their technologies. The Pregnabit system was discussed by Dr. Robert Woytoń, MD, PhD, who during his three-minute presentation described the device, its features and innovativeness. He also answered questions from the audience. More people could learn about our system at the Nestmedic stand in the exhibition area. It is there that we were honored to present the teleCTG Pregnabit to the special guests of the event, the Duke and the Duchess of Cambridge. The royal couple listened to a short description of the Pregnabit system showing interest in our device. The royal couple took part in a meeting with young entrepreneurs, a part of their first visit to Poland. This event gave rise to a new “Warsaw-London Bridge” initiative, whose aim is to assist companies from Poland and the UK and to make it easier for the Polish start-ups to get access to global markets. – Our solution and its international potential were once again recognized by independent experts who invited us to take part in this special event. We are very content of this, especially due to the fact that Nestmedic strategy is set on close co-operation with foreign medical organizations and resellers. During the “Warsaw-London Bridge” event we answered many questions, also technical ones, posed by British business people and British Embassy officers. We started a relationship, among others, with the Department for International Trade, an institution that is responsible for trade and investment in the UK. We are hoping that this relationship will allow us to market the Pregnabit system also to patients in Britain, says Patrycja Wizińska-Socha, MD, PhD, a co-founder and the CEO of Nestmedic SA.

As a part of our new co-operation we are going to conduct a business-focused pilot program under which Nestmedic is to provide research-qualified patients of selected Medicover Group medical centers a telemedical service based on the Pregnabit system. The pilot is the first stage of our activities. After the pilot gets successfully accomplished, we will aim to implement the mobile teleCTG Pregnabit in the Medicover centers. Medicover is a second chain of medical centers which wants to co-operate with Nestmedic. In Poland only, it provides medical services for 8,500 companies and 660,000 individuals. For over 10 years, the company has been aiming at developing telemedical services in its centers, enabling patients to use e-appointments or get medical advice on their phones. – Commencing co-operation with the Medicover Group we are positive that we are dealing with a very aware and experienced partner which knows the market of innovative telemedical solutions and – more importantly – has thoroughly researched patients’ needs. The fact that Medicover has chosen Pregnabit to telemonitor the wellbeing of the fetus and is going to make it available to pregnant women, only confirms that our solution meets not only patients’ expectations but also the ones of medical center management who want to offer their patients the highest value. We are happy that pregnant women monitored by the Medicover staff will quite soon be able to do a CTG test in any place and at any time using simultaneously the analytical support of the Telemonitoring Medical Center, says Patrycja Wizińska-Socha, MD PhD, a co-founder and the CEO of Nestmedic SA.

On June 12th, 2017 we went public on NewConnect. Many significant developments has had place during this first month. We have signed three letters of intent opening co-operation with the chains of Medicover and Blue Medica medical centers and a German reseller of telemedical devices. We have also embarked on developing Pregnabit II, a second generation of the device. – We are intensively getting prepared to implement our sales processes. Earlier this year, we announced that sales was to start in September. Bearing in mind the intensity of work and commitment, we are going to meet this deadline. We are aligning the sales communication to the needs of our target group which after beta-tests gave us important feedback on the costs and sales model, says Patrycja Wizińska-Socha, MD, PhD, a co-founder and the CEO of Nestmedic SA. A few weeks ago we started a co-operation with two chains of medical centers, Blue Medica and Medicover. The pilots in which Nestmedic is to provide the medical centers’ patients a telemedical service based on the Pregnabit system are to be implemented in the coming weeks. After successful completion of these stages of activities, the companies are planning to launch teleCTG Pregnabit on the market. The system has also attracted some interest from foreign organizations. In June, we signed a letter of intent with a German center for telemedical services, Zentrum für Telemedizin (ZTM) in Bad Kissingen, a reseller of telemedical solutions and services, mainly in Germany, but also in other European countries. – The mentioned three letters of intent are only the beginning. We have spoken with big international resellers who are very interested in starting co-operation with us. Soon we’ll be able to tell something more about the first agreements, adds Wizińska-Socha. Also, we already have a concept and funds for developing another generation of the device. Thanks to the grant of PLN 5m that we have received under the Szybka Ścieżka (Fast Track) program, our company is able to commence the R&D work on Pregnabit II, a second generation of the telemedical system – We have completed all the necessary paperwork, developed a budget plan and we are formally ready to commence the work on another version of our device. Most importantly, following the beta-testing and surveys with the patients, physicians and midwives who have used the Pregnabit system we know what new functionalities and facilities they need to work efficiently with a mobile CTG. Thanks to the grant from the NCRD we will be able to introduce them, says Anna Skotny, MD, PhD, General Manager and a co-founder of Nestmedic.